Clinical Research Directory
Browse clinical research sites, groups, and studies.
Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry
Sponsor: Novartis Pharmaceuticals
Summary
This is an observational single-arm descriptive cohort study based on the secondary use of data collected on iptacopan-treated patients with paroxysmal nocturnal hemoglobinuria (PNH) through the International PNH Interest Group (IPIG) PNH registry.
Official title: Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the Non-interventional IPIG PNH Registry
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2025-03-31
Completion Date
2029-10-01
Last Updated
2025-05-15
Healthy Volunteers
No
Conditions
Interventions
Iptacopan
Adult patients with PNH treated with iptacopan
Locations (1)
Novartis Investigative Site
Basel, Switzerland